Ascentage Pharma gets FDA ODD for APG-2575 in Waldenström macroglobulinemia

Ascentage Pharma has been granted orphan drug designation (ODD) for its Bcl-2 inhibitor APG-2575 from the US Food and Drug Administration (FDA) for the treatment ... Read More